Form 4 for TRDA Entrada Therapeutics, Inc.
Accepted 2022-01-18 00:00:00 ET · period of report 2022-01-13 · accession 0001104659-22-004980 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-18 | 2022-01-13 | TRDA | Doshi Dipal | Pres, CEO, Dir | M - OptEx | $1.74 | +10.0K | 184.5K | +6% | +$17.4K |
| D | 2022-01-18 | 2022-01-13 | TRDA | Doshi Dipal | Pres, CEO, Dir | M - OptEx | $0.00 | -10.0K | 400.0K | -2% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-13 | M | A | 10,000 | $1.74 | 184,460 | D | — | — | (F1) Consists of (i) 170,067 shares of common stock and (ii) 14,393 shares of restricted common stock issued upon early exercise of stock options. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-01-13 | M | D | 10,000 | $0.00 | 399,989 | D | $1.74 · — to 2029-05-14 | 10,000 Common Stock | (F2) 25% of the shares subject to this option vested and became exercisable on December 31, 2019, with the remaining 75% vesting in 36 equal monthly installments thereafter. |